Hirudin variants production by genetic engineered microbial factory
Research article published in Biotechnology & genetic engineering reviews (2018)
Abstract
Hirudin was discovered as an active anticoagulant in leech extracts almost 60 years ago. Since their initial discovery, hirudin and its variants have been produced with various anti-thrombotic, cancer cell inhibition, diabetic cataract treatment and anti-fatigue activities. Some hirudin variants have been approved for clinical use and released into the marketplace. Recent progress has seen made in relation to hirudin variants expressed in several well-established microbial hosts, including Escherichia coli, Saccharomyces cerevisiae, Pichia pastoris and others, with high levels of activity and yield. This review summarizes the current progress on hirudin production using microbial producers, and considers the outlook for future development.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Hirudin was discovered as an active anticoagulant in leech extracts almost 60 years ago. Since their initial discovery, hirudin and its variants have been produced with various anti-thrombotic, cancer cell inhibition, diabetic cataract treatment and anti-fatigue activities.
Por qué esto importa para la hirudoterapia
Esta revisión resume los avances en la producción de hirudin — descubierto como anticoagulante en extractos de sanguijuela — y sus variantes mediante hospedadores microbianos modificados genéticamente, incluyendo Escherichia coli, Saccharomyces cerevisiae y Pichia pastoris. Para el ámbito de la ASH, la producción de hirudin recombinante es relevante como una vía biotecnológica hacia un anticoagulante derivado de sanguijuela, ya que el resumen señala actividades reportadas que incluyen efectos antitrombóticos, inhibición de células cancerosas, tratamiento de cataratas diabéticas y efectos antifatiga, y algunas variantes aprobadas para uso clínico. Sin embargo, al tratarse de una revisión, sintetiza la literatura existente sin presentar nuevos datos experimentales, y no aborda la práctica de la hirudoterapia ni el secretoma salival más amplio de la sanguijuela.
Citación
Hirudin variants production by genetic engineered microbial factory.
Zhang J, Lan N · Biotechnology & genetic engineering reviews, 2018
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: March 18, 2026 · Última actualización del sitio: June 18, 2026